Guest: Rami Komrokji, MD

Guest: Natasha Johnson, MSN, APRN, AOCNP

Myelodysplastic syndromes (MDS) can require lifelong treatment.1 Learn how hematologist-oncologist Dr. Rami Komrokji and nurse practitioner Ms. Natasha Johnson approach their MDS protocol–from characterization, to diagnosis, to treatment. Together, they explain their process for scoring, transplants, and choosing a treatment regimen. They also share their experiences with INQOVI® (decitabine and cedazuridine), the only oral hypomethylating agent in the treatment of MDS, including chronic myelomonocytic leukemia.2

References: 1. Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096-1107. 2. INQOVI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2022.